Literature DB >> 20659413

Early spondyloarthritis: results from the pilot registry ESPIDEP.

S Muñoz-Fernández1, E de Miguel, T Cobo-Ibáñez, L Carmona, M Steiner, M A Descalzo, A Ferreira, A Balsa, E Martín-Mola.   

Abstract

OBJECTIVES: Studies on the incidence of spondyloarthritis (SpA) are scarce. Early SpA clinics should facilitate the detection of new cases as well as to decrease the diagnosis and treatment delay. However, the workload of such clinics has not been estimated.
METHODS: ESPIDEP is a pilot registry of patients with early SpA performed in Madrid, Spain. General practitioners (GPs) agreed and were trained to refer all patients under 45 with either inflammatory back pain or asymmetric arthritis of lower limbs with 3 to 24 month duration of symptoms to a specialised unit during 6 consecutive months. Case definition of SpA was based on the ESSG criteria. The success of the program was measured by: the satisfaction of the GPs regarding the referral process, the percentage of patients correctly derived according to the rheumatologist, the expected incidence of AS.
RESULTS: From a population of 111,941, the unit attended 52 patients, of whom 43 (83%) had been derived correctly and 35 were diagnosed with SpA (49% women; mean age 33+/-8; mean duration of symptoms 11+/-6 months; 46% HLA-B27 positive). The annual estimated incidence of SpA was 62.5 cases per 100,000 (95% CI: 45-87). Only 20/35 (57%) had radiological sacroiliitis and 4 (11.8%) fulfilled the modified New York criteria for ankylosing spondylitis (annual estimated incidence 7.2 per 100,000 (IC95%: 3.1-14.1)).
CONCLUSIONS: Around 60 cases of early SpA are expected annually in an area of 100,000. A referral based upon clinical parameters seems efficient. The planning of early SpA clinics may be based upon these figures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659413

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.

Authors:  Mariángeles González-Fernández; Elena Villamañán; Inmaculada Jiménez-Nácher; Francisco Moreno; Chamaida Plasencia; Francisco Gaya; Alicia Herrero; Alejandro Balsa
Journal:  Int J Clin Pharm       Date:  2018-09-08

Review 2.  The changing clinical picture and epidemiology of spondyloarthritis.

Authors:  Astrid van Tubergen
Journal:  Nat Rev Rheumatol       Date:  2014-11-11       Impact factor: 20.543

Review 3.  Diagnosis and classification in spondyloarthritis: identifying a chameleon.

Authors:  Astrid van Tubergen; Ulrich Weber
Journal:  Nat Rev Rheumatol       Date:  2012-03-27       Impact factor: 20.543

Review 4.  Epidemiology of spondyloarthritis.

Authors:  Carmen Stolwijk; Annelies Boonen; Astrid van Tubergen; John D Reveille
Journal:  Rheum Dis Clin North Am       Date:  2012-08       Impact factor: 2.670

5.  The incidence of spondyloarthritis in Slovenia.

Authors:  Alojzija Hočevar; Nataša Potočnik Pucelj; Rok Ješe; Milena Pavič-Nikolič; Matija Tomšič; Ziga Rotar
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

6.  Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology.

Authors:  José María Pego-Reigosa; Carlos Peña-Gil; David Rodríguez-Lorenzo; Irene Altabás-González; Naír Pérez-Gómez; John Henry Guzmán-Castro; Rodrigo Varela-Gestoso; Reyes Díaz-Lambarri; Alberto González-Carreró-López; Olga Míguez-Senra; Julia Bóveda-Fontán; Ángeles Charle-Crespo; Francisco Javier Caramés-Casal; Ceferino Barbazán-Álvarez; Íñigo Hernández-Rodríguez; Francisco Maceiras-Pan; Marina Rodríguez-López; Rafael Melero-González; José Benito Rodríguez-Fernández
Journal:  BMC Health Serv Res       Date:  2022-01-12       Impact factor: 2.655

7.  Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study.

Authors:  An Tran-Duy; Annelies Boonen; Mart A F J van de Laar; Johan L Severens
Journal:  Cost Eff Resour Alloc       Date:  2015-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.